Skip to main content

Table 2 Clinical and surgery-related baseline data between study groups

From: Not all patients benefit from the postoperative antifibrinolytic treatment: clinical evidence against the universal use of tranexamic acid following total knee arthroplasty

 

Group A (n = 112)

Group B (n = 158)

p

Female, n (%)

93 (83.04%)

129 (81.65%)

0.768

Age ± SD (year)

68.78 ± 7.60

67.23 ± 8.72

0.132*

Height ± SD (m)

1.56 ± 0.06

1.57 ± 0.06

0.185*

Weight ± SD (kg)

63.64 ± 9.50

61.84 ± 9.53

0.143*

BMI ± SD (kg/m2)

26.05 ± 3.88

25.12 ± 3.83

0.074

Major diagnosis

 KOA, n (%)

103 (91.96%)

140 (88.61%)

0.365

 KRA, n (%)

9 (8.04%)

18 (11.39%)

0.365

Left TKA, n (%)

55 (49.11%)

80 (50.63%)

0.805

ABT, n (%)

3 (2.68%)

6 (3.80%)

0.740

Intraoperative blood loss ± SD (mL)

65.41 ± 47.31

58.24 ± 59.89

0.295*

Operation time ± SD (min)

94.27 ± 21.38

92.19 ± 24.70

0.473*

LOS ± SD (day)

11.47 ± 3.34

12.22 ± 3.90

0.191*

Post-OP LOS ± SD (day)

6.17 ± 2.69

6.89 ± 3.29

0.101*

  1. SD standard deviation, BMI body mass index, KOA knee osteoarthritis, KRA knee rheumatoid arthritis, TKA total knee arthroplasty, ABT allogeneic blood transfusion, LOS length of stay, Post-OP postoperative
  2. *Independent-samples t test
  3. Chi-square test
  4. Mann–Whitney U test